Literature DB >> 27070264

Reprogramming cancer cells: overview & current progress.

Kian Lam Lim1, Hoon Koon Teoh1,2, Pei Feng Choong1,2, Hui Xin Teh1, Soon Keng Cheong1, Tunku Kamarul3.   

Abstract

INTRODUCTION: Cancer is a disease with genetic and epigenetic origins, and the possible effects of reprogramming cancer cells using the defined sets of transcription factors remain largely uninvestigated. In the handful of publications available so far, findings have shown that reprogramming cancer cells changed the characteristics of the cells to differ from the parental cancer cells. These findings indicated the possibility of utilizing reprogramming technology to create a disease model in the laboratory to be used in studying the molecular pathogenesis or for drug screening of a particular cancer model. AREAS COVERED: Despite numerous methods employed in generating induced pluripotent stem cells (iPSCs) from cancer cells only a few studies have successfully reprogrammed malignant human cells. In this review we will provide an overview on i) methods to reprogram cancer cells, ii) characterization of the reprogrammed cancer cells, and iii) the differential effects of reprogramming on malignancy, epigenetics and response of the cancer cells to chemotherapeutic agents. EXPERT OPINION: Continued technical progress in cancer cell reprogramming technology will be instrumental for more refined in vitro disease models and ultimately for the development of directed and personalized therapy for cancer patients in the future.

Entities:  

Keywords:  iPC; iPSC; pluripotent; reprogramming cancer cells; stem cells

Mesh:

Substances:

Year:  2016        PMID: 27070264     DOI: 10.1517/14712598.2016.1174211

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  8 in total

1.  ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

Authors:  Vivek Shukla; Mahadev Rao; Hongen Zhang; Jeanette Beers; Darawalee Wangsa; Danny Wangsa; Floryne O Buishand; Yonghong Wang; Zhiya Yu; Holly S Stevenson; Emily S Reardon; Kaitlin C McLoughlin; Andrew S Kaufman; Eden C Payabyab; Julie A Hong; Mary Zhang; Sean Davis; Daniel Edelman; Guokai Chen; Markku M Miettinen; Nicholas P Restifo; Thomas Ried; Paul A Meltzer; David S Schrump
Journal:  Cancer Res       Date:  2017-09-21       Impact factor: 12.701

2.  Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer.

Authors:  Yingkun Xu; Dan Shu; Meiying Shen; Qiulin Wu; Yang Peng; Li Liu; Zhenrong Tang; Shun Gao; Yuan Wang; Shengchun Liu
Journal:  J Immunol Res       Date:  2022-06-02       Impact factor: 4.493

3.  Renal carcinoma/kidney progenitor cell chimera organoid as a novel tumorigenesis gene discovery model.

Authors:  Qi Xu; Sanna Junttila; Andreas Scherer; Khem Raj Giri; Oona Kivelä; Ilya Skovorodkin; Juha Röning; Susan E Quaggin; Hans-Peter Marti; Jingdong Shan; Anatoly Samoylenko; Seppo J Vainio
Journal:  Dis Model Mech       Date:  2017-12-19       Impact factor: 5.758

Review 4.  Modeling the process of human tumorigenesis.

Authors:  Sneha Balani; Long V Nguyen; Connie J Eaves
Journal:  Nat Commun       Date:  2017-05-25       Impact factor: 14.919

5.  Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype.

Authors:  Michele Sook Yuin Hiew; Han Ping Cheng; Chiu-Jung Huang; Kowit Yu Chong; Soon Keng Cheong; Kong Bung Choo; Tunku Kamarul
Journal:  J Biomed Sci       Date:  2018-07-19       Impact factor: 8.410

6.  Tendency of K562 Chronic Myeloid Leukemia Cells Towards Cell Reprogramming

Authors:  Açelya Yılmazer Aktuna
Journal:  Turk J Haematol       Date:  2018-05-21       Impact factor: 1.831

Review 7.  Cancer cells as a new source of induced pluripotent stem cells.

Authors:  Azam Shamsian; Roxana Sahebnasagh; Amir Norouzy; Safin Hassan Hussein; Mohammad Hossein Ghahremani; Zahra Azizi
Journal:  Stem Cell Res Ther       Date:  2022-09-05       Impact factor: 8.079

8.  Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast Cancer.

Authors:  Yingkun Xu; Yudi Jin; Shun Gao; Yuan Wang; Chi Qu; Yinan Wu; Nan Ding; Yuran Dai; Linshan Jiang; Shengchun Liu
Journal:  J Oncol       Date:  2022-08-25       Impact factor: 4.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.